<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Previous labeling and guidelines recommended initiating erythropoiesis agents (ESAs) for chemotherapy-induced <z:hpo ids='HP_0001903'>anemia</z:hpo> (CIA) at <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (Hb) levels &lt; 11 g/dL, maintaining near 12 g/dL, and withholding at &gt; or = 13 g/dL </plain></SENT>
<SENT sid="1" pm="."><plain>This study analyzed adherence with recommendations in administration of darbepoetin (<z:mp ids='MP_0000273'>DA</z:mp>) to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of Hb levels at which <z:mp ids='MP_0000273'>DA</z:mp> was administered using Varian electronic medical records (EMRs) </plain></SENT>
<SENT sid="3" pm="."><plain>The dataset comprises 141 694 cancer patients from 82 sites across 13 states </plain></SENT>
<SENT sid="4" pm="."><plain>The study evaluated <z:mp ids='MP_0000273'>DA</z:mp> administrations with respect to recorded Hb for 8988 patients from 1/1/05 to 5/31/07 </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASURES: Proportion of <z:mp ids='MP_0000273'>DA</z:mp> administrations at Hb &gt; or = 12 and Hb &gt; or = 13 g/dL </plain></SENT>
<SENT sid="6" pm="."><plain>Hb level was analyzed for <z:hpo ids='HP_0000001'>all</z:hpo> administrations, stratified by year and <z:hpo ids='HP_0001903'>anemia</z:hpo> type (CIA, <z:hpo ids='HP_0001903'>anemia</z:hpo>-of-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>) </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: There were 51 111 <z:mp ids='MP_0000273'>DA</z:mp> administrations with Hb results </plain></SENT>
<SENT sid="8" pm="."><plain>The proportion of administrations at Hb &gt; or = 12 g/dL was 7.2% and at Hb &gt; or = 13 g/dL was 0.6%, and for CIA 6.9%/0.6%, <z:hpo ids='HP_0001903'>anemia</z:hpo> of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (AOC) 8.8%/0.8%, and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) 6.5%/0.6% </plain></SENT>
<SENT sid="9" pm="."><plain>The proportion of <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0000273'>DA</z:mp> administrations at Hb &gt; or = 12 g/dL and &gt; or = 13 g/dL declined from 8.6% to 5.3% (p &lt; 0.0001) and from 0.7% to 0.4% (p &lt; 0.0007), respectively during 1/1/05-5/31/07 </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In this population, <z:mp ids='MP_0000273'>DA</z:mp> administration at Hb &gt; or = 12 g/dL and Hb &gt; or = 13 g/dL occurred in 7.2% and 0.6% of administrations, respectively, a approximately 93% adherence rate with recommendations </plain></SENT>
<SENT sid="11" pm="."><plain>Further research is required to understand dose titrations at Hb 12-13 g/dL, and whether similar patterns are observed for other ESAs, and in other practice settings </plain></SENT>
<SENT sid="12" pm="."><plain>This study provides context for the debate regarding the utilization, benefits and risks of ESAs in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
</text></document>